Please take a listen to a conversation with Dr. Jim DeMesa, who is the President and CEO of Emerald Health Pharmaceuticals. Emerald Health Pharmaceuticals (EHP) is a private clinical-stage biotechnology company with a portfolio of novel, patented new chemical entities (NCEs) derived from the non-psychoactive cannabinoids, cannabidiol (CBD) and cannabigerol (CBG).
In preclinical studies, these product candidates, EHP-101, a CBD-derivative, and EHP-102, a CBG-derivative, have demonstrated the potential to be disease-modifying in specific neurodegenerative, autoimmune, inflammatory, and fibrotic diseases with significant unmet medical need. EHP’s four initial therapeutic areas of focus include systemic sclerosis, multiple sclerosis, Parkinson’s disease and Huntington’s disease.
With a multi-pronged mechanism of action (MOA), these NCEs are well positioned as first-in-class disease-modifying molecules for these targeted diseases, which currently have no cure. In this conversation, Dr. DeMesa also discussed the process of bringing 2 different cannabinoid-derivatives to market for several hard to treat orphan disease states.
In particular, we discussed trial design and product formulation for systemic sclerosis and multiple sclerosis, 2 progressive inflammatory diseases with significant disease burden and no known cures.
Outside of his role at EHP, in the past Dr. DeMesa has been a writer, speaker, and “happiness” coach, partnering with Anthony Robbins to improve the quality of life for healthcare practitioners. Dr. DeMesa has published books intended to improve peoples’ lives. The first book is called simply, BeHappy! He has also written two e-books called “BeHappy at Work” and “A Guide to Healthy Living”, all of which are available at www.BeHappy101.com.
For more information on EHP, please refer to: https://emeraldpharma.life/our-focus/